CytomX Therapeutics to Present at Upcoming December Investor Conferences
Rhea-AI Summary
CytomX Therapeutics (NASDAQ: CTMX) announced management will present at two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 (fireside chat at 1:45 p.m. ET) in Coral Gables, FL, and the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 (fireside chat at 1:00 p.m. ET) in New York, NY.
A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will hold one-on-one meetings with registered conference attendees.
Positive
- None.
Negative
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in December.
8th Annual Evercore Healthcare Conference
Date: Tuesday, December 2, 2025
Fireside Chat: 1:45 p.m. ET
Location: Coral Gables, FL
Piper Sandler 37th Annual Healthcare Conference
Date: Thursday, December 4, 2025
Fireside Chat: 1:00 p.m. ET
Location: New York, NY
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
When will CytomX (CTMX) present at the Evercore Healthcare Conference in December 2025?
What time is the CytomX (CTMX) presentation at the Piper Sandler Healthcare Conference?
Will CytomX (CTMX) webcast its December 2025 conference presentations?
Can investors schedule one-on-one meetings with CytomX (CTMX) management at the December conferences?
Where can I find slides or a replay of CytomX (CTMX) December 2025 presentations?
